<DOC>
	<DOC>NCT00634361</DOC>
	<brief_summary>This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.</brief_summary>
	<brief_title>Ethyl-EPA Treatment of Prodromal Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>meets criteria for schizophrenia prodrome any lifetime antipsychotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>